Description: The KGP130 monoclonal antibody reacts with mouse gp130, also known as CD130. gp130 is a 130 kD Type-I transmembrane glycoprotein containing a 597 amino acid extracellular domain, a single transmembrane domain, and a 277 amino acid cytoplasmic domain. gp130 is a subunit of several heterodimeric cell-surface receptors, including receptors for IL-6, IL-11, IL-27, Oncostatin M, and Leukemia Inhibitory Factor (LIF). The gp130 protein has also been found to exist in a soluble form, which is capable of inhibiting IL-6 signaling. gp130 is expressed mainly on T cells, monocytes, endothelial cells, activated B cells, and plasma cells, and is expressed at lower levels on most leukocytes and epithelial cells. In response to ligand binding, gp130 becomes tyrosine phosphorylated, leading to activation of several signaling pathways including the PI3 kinase, Ras-MAPk and Stat pathways.
Preincubation of mouse splenic T cells with IL-6 is capable of blocking the interaction of KGP130 with gp130, suggesting that the KGP130 binding site lies near the IL-6 interaction domain. Reactivity of KGP130 towards human gp130 has not been observed.